Haemonetics (HAE) to acquire Vivasure Medical Limited for 100 million euros upfront plus potential milestone payments.

Boston will inherit products, including Penumbra’s Lightning thrombectomy systems, to advance its vascular care provision.

Boston Scientific to acquire thrombectomy firm Penumbra for $14.5bn, expanding its cardiovascular portfolio as deal reshapes ...

Haemonetics Corporation announced the acquisition of Vivasure Medical Limited, an Ireland-based developer of technology for per ...

Boston Scientific Corporation (NYSE: BSX) and Penumbra, Inc., (NYSE: PEN) today announced the companies have entered into a ...

Haemonetics has acquired Vivasure, a developer of next-generation technology for percutaneous vessel closure, in a deal worth ...

Boston Scientific enters agreement to acquire Penumbra for $14.5 billion: Marlborough, Massachusetts Friday, January 16, 2026, 14:30 Hrs [IST] Boston Scientific Corporation and Pe ...

Boston Scientific has agreed to acquire Penumbra in a deal worth about $14.5 billion. Boston Scientific has agreed to acquire ...

Boston Scientific Corporation and Penumbra, Inc. announced that the companies have entered into a definitive agreement under ...

$11 million in proceeds expected to be received during 2026, with remainder of expected proceeds to be received in future revenue earnouts Vivasure Medical Limited (“Vivasure”) has been a strategic ...

Blood vessel changes in the eye mirror brain damage in mice with a gene variant linked to dementia, potentially offering ...

Haemonetics' acquisition of Vivasure adds PerQseal Elite, advancing large-bore closure solutions for TAVR and EVAR markets.